187 related articles for article (PubMed ID: 15286710)
1. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein.
Xia SJ; Barr FG
Oncogene; 2004 Sep; 23(41):6864-71. PubMed ID: 15286710
[TBL] [Abstract][Full Text] [Related]
2. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
Sublett JE; Jeon IS; Shapiro DN
Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639
[TBL] [Abstract][Full Text] [Related]
3. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
Xia SJ; Rajput P; Strzelecki DM; Barr FG
Lab Invest; 2007 Apr; 87(4):318-25. PubMed ID: 17297479
[TBL] [Abstract][Full Text] [Related]
4. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
[TBL] [Abstract][Full Text] [Related]
5. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.
Lam PY; Sublett JE; Hollenbach AD; Roussel MF
Mol Cell Biol; 1999 Jan; 19(1):594-601. PubMed ID: 9858583
[TBL] [Abstract][Full Text] [Related]
7. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene.
Ayyanathan K; Fredericks WJ; Berking C; Herlyn M; Balakrishnan C; Gunther E; Rauscher FJ
Cancer Res; 2000 Oct; 60(20):5803-14. PubMed ID: 11059777
[TBL] [Abstract][Full Text] [Related]
8. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ
Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659
[TBL] [Abstract][Full Text] [Related]
9. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
10. Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma.
Du S; Lawrence EJ; Strzelecki D; Rajput P; Xia SJ; Gottesman DM; Barr FG
Int J Cancer; 2005 May; 115(1):85-92. PubMed ID: 15688409
[TBL] [Abstract][Full Text] [Related]
11. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
Bennicelli JL; Edwards RH; Barr FG
Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
[TBL] [Abstract][Full Text] [Related]
12. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma.
Kempf BE; Vogt PK
Cell Growth Differ; 1999 Dec; 10(12):813-8. PubMed ID: 10616906
[TBL] [Abstract][Full Text] [Related]
13. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.
Scheidler S; Fredericks WJ; Rauscher FJ; Barr FG; Vogt PK
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9805-9. PubMed ID: 8790412
[TBL] [Abstract][Full Text] [Related]
14. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3.
Anderson MJ; Shelton GD; Cavenee WK; Arden KC
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1589-94. PubMed ID: 11171995
[TBL] [Abstract][Full Text] [Related]
15. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
16. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
Bennicelli JL; Advani S; Schäfer BW; Barr FG
Oncogene; 1999 Jul; 18(30):4348-56. PubMed ID: 10439042
[TBL] [Abstract][Full Text] [Related]
17. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
19. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression.
Tomescu O; Xia SJ; Strezlecki D; Bennicelli JL; Ginsberg J; Pawel B; Barr FG
Lab Invest; 2004 Aug; 84(8):1060-70. PubMed ID: 15184910
[TBL] [Abstract][Full Text] [Related]
20. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
